ClinicalTrials.gg
RecruitingNCT05004129REACH CDM XUpdated May 28, 2025

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

A Phase 2/3 interventional study of Tideglusib in Congenital Myotonic Dystrophy, sponsored by AMO Pharma Limited. Recruiting at 14 sites in 4 countries. Open to participants aged 6 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by AMO Pharma Limited · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
6 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Planned enrollment
6th of 22
76 · median 46
Started
2021
with 3 others
Phase 2/3
2 of 43
1 open now
Primary completion
2026-12
later than 1 of 26 live
Registered
17th of 43
by date
Lead sponsor
2 of 43
AMO Pharma Limited

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is one of 2 in phase 2/3, reaches primary completion later than 1 of the 26 other live ones, and was the 17th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 6 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who are treatment naïve.

Read the detailed description

This is an open-label study of either a weight-adjusted 1000 mg fixed dose or a weight banded fixed dose of tideglusib across a 52-week treatment period with an open-ended optional extended access period. The subjects are children and adolescents with Congenital DM1 who participated in the antecedent AMO-02-MD-2-003 study or individuals with either Congenital or Childhood onset DM1 who are treatment naïve.

03

Conditions studied

  • Congenital Myotonic Dystrophy

Browse trials for

Keywords

  • Tideglusib
  • AMO-02-MD-2-004
  • Congenital Myotonic Dystrophy
  • Myotonic Dystrophy
  • Dystrophia Myotonica
  • Myotonia Atrophica
  • Myotonia Dystrophica
  • Myotonic Dystrophy, Congenital
  • Steinert Disease
  • Steinert Myotonic Dystrophy
  • Steinert's Disease
04

Who can participate

Ages eligible
6 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Subjects who do not enter this study directly from completing the AMO-02-MD-2-003 study (i.e. subjects who did not complete AMO-02-MD-2-003, subjects who completed AMO-02-MD-2-003 but did not directly rollover or subjects who are re-entering AMO-02-MD-2-004), will not be considered eligible for the study without meeting all of the criteria below:

  1. Subjects under study must be individuals with a diagnosis of Congenital or Childhood Onset DM1.
  2. Diagnosis must be genetically confirmed
  3. Subjects must be male or female aged ≥6 years to ≤45 years at Screening
  4. Subjects must have a Clinical Global Impression - Severity (CGI-S) score of 3 or greater at Screening (V-1)
  5. Written, voluntary must be obtained before any study related procedures are conducted. Where a parent or legally authorized representative (LAR) provides consent, there must also be assent from the subject (as required by local regulations)
  6. Subject's caregiver must be willing and able to support participation for duration of study
  7. Subject must be willing and able to comply with the required food intake restrictions as outlined per protocol

Subjects entering directly from completing the antecedent AMO-02-MD-2-003 study will not be considered eligible for the study without meeting all of the criteria below:

  1. Subjects who have completed the antecedent AMO-02-MD-2-003 study through V11
  2. Written, voluntary informed consent must be obtained before any study related procedures are conducted. Where a parent or LAR provides consent, there must also be assent from the subject (as required by local regulations)
  3. Subject's caregiver must be willing and able to support participation for duration of study
  4. Subject must be willing and able to comply with the required food intake restrictions as outlined per protocol

Key Exclusion Criteria:

  1. (BMI) less than 13.5 kg/m² or greater than 40 kg/m²
  2. New or change in medications/therapies within 4 weeks prior to Eligibility/Baseline Visit
  3. Use within 4 weeks prior to Eligibility/Baseline Visit of strong inhibitors (eg.clarithromycin, telithromycin, ketoconazole, itraconazole, posaconazole, nefazodone, idinavir and ritonavir)
  4. Concurrent use of drugs metabolized by CYP3A4 with a narrow therapeutic window (e.g. warfarin and digitoxin)
  5. Current enrollment in a clinical trial of an drug or enrollment in a clinical trial of an investigational drug in the last 6 months other than the AMO-02- MD-2-003 study
  6. Existing or historical medical conditions or complications (eg. neurological, cardiovascular, renal, hepatic, gastrointestinal, endocrine or respiratory disease) that may impact the interpretability of the study results
  7. to tideglusib or any components of its formulation including allergy to strawberry
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Tideglusib

    Weight adjusted or weight banded tideglusib, orally, once daily

    Drug: Tideglusib

Interventions

  • Tideglusib dosing will be weight-adjusted at 400 mg, 600 mg, or 1000 mg dose levels, or weight banded fixed doses of 400 mg, 600 mg, 800 mg or 1000 mg, with each subject starting at a weight-adjusted 400 mg dose level for 2 weeks, then up titrating to a weight-adjusted 600 mg dose level for the next 2 weeks.

06

What researchers measure

Primary outcomes

  1. Safety (Adverse Events)

    The incidence of AEs, including SAEs, and abnormal findings in objective assessments (e.g. laboratory values, ECGs and vital signs) from Screening to Enrolment (where applicable), from Enrolment to End of Treatment (52 Weeks), and End of Treatment to the End of Follow-up period.

    Time frame: 52 Weeks

  2. Safety (Adverse Events) - With Optional Expanded Access

    The incidence of AEs, including SAEs, and abnormal findings in objective assessments (e.g. laboratory values, ECGs and vital signs) from End of Treatment to End of Optional Extended Access, and End of Optional Extended Access to the End of Follow-up period.

    Time frame: Week 60 and every 8 weeks thereafter up until discontinuation or study closure, assessed up to Week 132

  3. Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS)

    The Clinician-completed Congenital DM1 Rating Scale is an 11-item rating scale completed by the clinician to score the symptom severity of domains that are clinically relevant in Congenital DM1.

    Time frame: 52 Weeks

Secondary outcomes

  1. Clinician-Completed Congenital DM1 Rating Scale (CDM1-RS) - With Optional Expanded Access

    The Clinician-completed Congenital DM1 Rating Scale is an 11-item rating scale completed by the clinician to score the symptom severity of domains that are clinically relevant in Congenital DM1.

    Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132

  2. Clinical Global Impressions Improvement Scale (CGI-I)

    The CGI-I requires the clinician to rate how much the subject's illness has changed (improved, worsened or stayed the same) relative to a baseline state.

    Time frame: 54 Weeks

  3. Clinical Global Impressions Improvement Scale (CGI-I) - With Optional Expanded Access

    The CGI-I requires the clinician to rate how much the subject's illness has changed (improved, worsened or stayed the same) relative to a baseline state.

    Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132

  4. Top 3 Caregiver Concerns Visual Analogue Scale (VAS) score

    The Top 3 concerns VAS allows caregivers to identify their main three causes of concern, related to the subject's myotonic dystrophy, rather than these being pre-specified within a scale and then rating how these concerns have changed at specific time-points during the study.

    Time frame: 54 weeks

  5. Top 3 Caregiver Concerns Visual Analogue Scale (VAS) score - With Optional Expanded Access

    The Top 3 concerns VAS allows caregivers to identify their main three causes of concern, related to the subject's myotonic dystrophy, rather than these being pre-specified within a scale and then rating how these concerns have changed at specific time-points during the study.

    Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132

  6. Caregiver Completed Congenital DM1 Rating Scale (CC-CDM1-RS)

    CC-CDM1-RS provides a caregiver assessment of the subject on symptoms that may occur in individuals with CDM1. There are a total of 11 symptoms that the caregiver is asked to rate from 0 to 4 based on overall severity.

    Time frame: 52 weeks

  7. Caregiver Completed Congenital DM1 Rating Scale (CC-CDM1-RS) - With Optional Expanded Access

    CC-CDM1-RS provides a caregiver assessment of the subject on symptoms that may occur in individuals with CDM1. There are a total of 11 symptoms that the caregiver is asked to rate from 0 to 4 based on overall severity.

    Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132

  8. Clinical Global Impressions Severity Scale (CGI-S)

    The CGI-S is a 7-point Likert type scale that requires the clinician to rate the severity of the subject's illness at the time of assessment, relative to the clinician's past experience with subjects who have the same diagnosis.

    Time frame: 54 weeks

  9. Clinical Global Impressions Severity Scale (CGI-S) - With Optional Expanded Access

    The CGI-S is a 7-point Likert type scale that requires the clinician to rate the severity of the subject's illness at the time of assessment, relative to the clinician's past experience with subjects who have the same diagnosis.

    Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132

  10. Autism Behavior Inventory- Clinician (ABI-C)

    ABI-C is a 14 item rating scale requires the clinician to assess the core features of Autism Spectrum Disorder as well as common associated behaviors.

    Time frame: 52 Weeks

  11. Socialization, Communication, Daily Living, and Adaptive Behavior Composite standard scores of the Vineland Adaptive Behavior Scale - Survey Interview

    The Vineland Adaptive Behavior Scales require the clinician to measure personal and social skills needed for everyday living. It provides a targeted assessment of adaptive behavior via a semi-structured parent or caregiver interview.

    Time frame: 52 Weeks

  12. 10-meter walk-run test

    The 10-meter walk/run test is a performance measure used to assess walking speed in meters per second over a short distance. It can be used as an assessment of functional mobility.

    Time frame: 52 Weeks

  13. Plasma Troponin T levels

    Troponin T can be used as a biomarker for cardiac dysfunction but can also be elevated in DM1 patients without evident cardiac dysfunction.

    Time frame: 52 Weeks

  14. Plasma Troponin T levels - With Optional Expanded Access

    Troponin T can be used as a biomarker for cardiac dysfunction but can also be elevated in DM1 patients without evident cardiac dysfunction.

    Time frame: Week 68 and every 16 weeks thereafter up until discontinuation or study closure, assessed up to Week 132

  15. Blood Leukocytes CTG Repeats

    A genomic blood sample will be taken from all subjects to confirm the average number of repeats at sampling and estimate the number of leukocyte CTG repeats inherited for an individual subject.

    Time frame: Baseline and Week 52

  16. Blood Leukocytes CTG Repeats - With Optional Expanded Access

    A genomic blood sample will be taken from all subjects to confirm the average number of repeats at sampling and estimate the number of leukocyte CTG repeats inherited for an individual subject. For subjects that have already passed Week 52 at implementation of this endpoint, a single genomic blood sample will taken at the next in-clinic OEA visit.

    Time frame: Week 52 or later

07

Study locations

11 of 14 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Dec 2026, 64 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2021
First posted
Aug 13, 2021
StartActual
Aug 23, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05004129
Lead sponsor
AMO Pharma Limited
Responsible party
Sponsor
First posted
Aug 13, 2021
Start date
Aug 23, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 28, 2025

Study contacts

Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM
study director · AMO Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tideglusib

Start the discussion